Categories
Posts

VeonGen Therapeutics Secures FDA Alignment on Phase 3 Development of VG801 for …

The company is also advancing its Virtual Reality Visual Test (VRVT) through the FDA’s Rare Disease Endpoint Advancement Pilot Program as a potential …

Generated by Feedzy